![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_open_medium.gif)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_restricted_medium.gif)
Formulation and Evaluation of Mucoadhesive Buccal Patches of Terbutaline Sulphate
Subscribe/Renew Journal
The aim of the study was to develop and optimize formulations of mucoadhesive patches of Terbutaline sulphate. The patches were prepared by the solvent casting method using Hydroxyl propyl methyl cellulose (HPMC E-15) as basic polymer along with Carbopol 934, Eudragit RL 100, and Chitosan were taken in different concentration. The patches were found to be smooth in appearance, uniform in thickness, weight uniformity, drug content, swelling behavior, and surface pH. Terbutaline Sulphate Buccal patch of Formulation 5 (TBP5) containing 400 mg of HPMC, 200 mg of Eudragit RL 100 have optimum bioadhesive strength, in-vitro residence time showed a release of 83.40 % after 15 hours and can meet the ideal requirement for sustained release buccal devices, which can be good way to bypass the extensive hepatic first pass metabolism and increase bioavailability.
Keywords
Mucoadhesive, Buccal Patches, Terbutaline Sulphate, HPMC, Eudragit.
Subscription
Login to verify subscription
User
Font Size
Information
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 358
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 2